Inhibrx Inc.

Inhibrx Inc. a clinical-stage biopharmaceutical company focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109 a tetravalent agonist of death receptor 5 which is in Phase 2 clinical trials to treat cancers such as chondrosarcoma mesothelioma and pancreatic adenocarcinoma; INBRX-105 a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101 an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106 a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio Inc. Bristol-Myers Squibb Company and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla California.